Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | APP | P05067 | 4/20 | 0.74 |
| ▸ | SNCA | P37840 | 4/20 | 0.74 |
| ▸ | METAP1 | P53582 | 1/20 | 0.69 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | PLK1 | P53350 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448894 | 1.00 | MAPT (0.74) | MAPTAPPSNCAMETAP1PLK4 | |
| SCHEMBL5470412 | 1.00 | MAPT (0.74) | MAPTAPPSNCAMETAP1PLK4 | |
| SCHEMBL5363189 | 0.85 | METAP1 (0.63) | MAPTAPPSNCAMETAP1PLK4 | |
| SCHEMBL8484153 | 0.85 | APP (1.00) | MAPTAPPSNCAMETAP1PLK4 | |
| SCHEMBL16442343 | 0.85 | APP (1.00) | MAPTAPPSNCAMETAP1PLK4 | |
| SCHEMBL8484149 | 0.85 | APP (1.00) | MAPTAPPSNCAMETAP1PLK4 | |
| SCHEMBL31219496 | 0.83 | GSK3B (0.74) | MAPTAPPSNCAMETAP1GSK3B | |
| SCHEMBL3757258 | 0.83 | GSK3B (0.74) | MAPTAPPSNCAMETAP1GSK3B | |
| SCHEMBL3757263 | 0.83 | GSK3B (0.74) | MAPTAPPSNCAMETAP1GSK3B | |
| SCHEMBL5695409 | 0.82 | MAPT (0.62) | MAPTAPPSNCAMETAP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| US-20150038543-A1 | ANTI-GLYCATION PROPERTIES OF OXINDOLE DERIVATIVES | CHOUDHARY MUHAMMAD IQBAL (PK) | 2015-02-05 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | MAPT 1309/4885APP 2886/4885SNCA 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.